Adherium Ltd (ASX:ADR) will provide its Smartinhaler devices to AstraZeneca Australia for a commercial pilot program in patients with asthma and chronic obstructive pulmonary disease.
Smartinhaler is a touch-enabled device that provides alerts to improve medication adherence and health outcomes for patients.
AstraZeneca will use Adherium’s devices, mobile app and cloud platform and aims to show how these devices improve medication adherence in patients.
Notably, clinical studies in the past have proven that the Smartinhaler platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults.
Adherium is supplying the technology for this program under a long-term master supply and development agreement already entered into with AstraZeneca.
The company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.
Adherium will now look to accelerate its expansion in North America after the opening of its office in San Mateo, California earlier this month.
Adherium is well funded with $27.2 million in cash as at 30 June 2016.
Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.